Key Positives From The Results
The Surveillance & FA and Mobility & Healthcare segments delivered double-digit top- and bottom-line growth, offsetting declines in photography-related OEM products and demonstrating the benefits of portfolio diversification. Both revenue and profit exceeded plan, establishing a solid foundation toward achieving full-year operating income of JPY 18.5B.
- Surveillance & FA segmentposted revenue of JPY 3.6B (+25.2% YoY) and operating income of JPY 520M (+27.9% YoY), with double-digit revenue growth across all categories. The completion of inventory adjustments in the FA space was a key contributor
- Mobility & Healthcare segmentrecorded revenue of JPY 3.57B (+19.1% YoY), with medical lenses surging ~1.6x YoY. Automotive also delivered double-digit growth driven by ADAS demand
- Proprietary-brand photography lensesreturned to positive growth in Europe, reversing a period of weakness, while Japan and the US also posted double-digit growth. Growth was confirmed across all major regions except China
- FX tailwindcontributed JPY 530M to revenue and JPY 300M to operating income, with yen weakness underpinning results
- Unallocable corporate costsnarrowed by JPY 333M YoY, with improved indirect cost efficiency providing additional operating income support
Key Concerns From The Results
Photography-related revenue came in at JPY 11.3B (−16.7% YoY) and operating income at JPY 2.39B (−37.2% YoY), as weak sales of certain OEM product models persisted. Gross margin declined to 44.4% (−1.4pt YoY), highlighting the challenge of absorbing rising raw material and labor costs.
- OEM productsdeclined sharply, down −38.7% YoY on a value basis. The order weakness that began in H2 of the prior year has now persisted for over two quarters, with the timing of recovery unclear
- Gross marginof 44.4% (−1.4pt YoY). Unfavorable product mix eroded gross profit by JPY 320M, while volume declines reduced gross profit by JPY 690M, together weighing on operating income
- FX lossesexpanded to JPY 186M (vs. JPY 41M in the prior year), pushing recurring profit margin down to 18.2% (−3.6pt YoY). Deterioration in non-operating items weighed on net income
- Inventoriesrose to JPY 18.98B (inventory turnover of 3.1 months vs. 2.4 months at prior FY-end). Inventory build amid OEM deceleration warrants close monitoring
- China market: proprietary-brand lenses plunged −57% YoY due to excess channel inventory. The recovery outlook for this market remains uncertain
Focus Areas / Items To Monitor Going Forward
- Recovery scenario for underperforming OEM product models from Q2 onward. H2 order trends are critical to achieving the full-year OEM plan of JPY 24B (−2.9% YoY)
- The company plans to launch 10+ new products in FY2026. With the A078 already released for both Sony E-mount and Nikon Z-mount in Q1, at least 8 additional models are slated for Q2 and beyond — execution feasibility and P&L impact require assessment
- US tariff impact was JPY −110M in Q1. Quantitative assessment needed of how evolving trade policy risks from Q2 onward could affect guidance assumptions
- Specific drivers behind the sales weakness in certain OEM product models and expected timing of recovery
- Launch schedule for the 10+ new products in FY2026, with breakdown by mount type
- Outlook for resolving excess inventory in China and concrete measures to restore sales
- Pricing strategy and supply chain adjustments in response to additional US tariff exposure
- Timeline for revenue contribution from the strategic investment in Light Touch Technology
- Sustainability of the rapid growth in medical lenses (~1.6x YoY) and interim milestones toward the FY2030 JPY 3B target
- Drivers behind the deterioration in inventory turnover (2.4 → 3.1 months) and plans to normalize
- Development framework and camera-maker collaboration status for accelerating Canon RF-mount lineup expansion
- M&A strategy in pursuit of the long-term vision of becoming a "comprehensive optical and sensing solutions company"
- FX assumptions for FY2026 (USD/JPY 148, EUR/JPY 175) and hedging status given current spot rate divergence
Key Financial Highlights
| Item | Value | YoY |
|---|---|---|
| Revenue | JPY 18,485M | −5.0% |
| Gross Profit | JPY 8,209M | −7.9% |
| Gross Profit Margin | 44.4% | −1.4pt |
| SG&A | JPY 4,767M | +2.0% |
| Operating Income | JPY 3,441M | −18.7% |
| Operating Income Margin | 18.6% | −3.2pt |
| Recurring Profit | JPY 3,363M | −20.6% |
| Net Income Attributable to Owners of Parent Company (Quarterly) | JPY 2,712M | −4.5% |
| EPS | JPY 16.82 | −3.6% |
| Comprehensive Income | JPY 3,212M | +198.2% |
The JPY −793M YoY decline in operating income breaks down as follows: FX tailwind +300, non-R&D SG&A reduction +160, higher R&D costs −140, US tariffs −110, unfavorable product mix −320, volume-driven gross profit decline −690, and other +6. Net income decline was mitigated by the non-recurrence of a prior-year extraordinary loss (JPY 407M loss on sale of investment securities).
Performance By Business Segment
| Segment | Revenue | YoY | Operating Income | YoY | Margin |
|---|---|---|---|---|---|
| Photography-Related | JPY 11,305M | −16.7% | JPY 2,390M | −37.2% | 21.1% |
| Surveillance & FA-Related | JPY 3,602M | +25.2% | JPY 523M | +27.9% | 14.5% |
| Mobility & Healthcare, Others | JPY 3,577M | +19.1% | JPY 901M | +23.7% | 25.2% |
| Adjustments | - | - | JPY −373M | - | - |
| Total | JPY 18,485M | −5.0% | JPY 3,441M | −18.7% | 18.6% |
- Surveillance camera lenses: Revenue of JPY 2.1B (+28.8% YoY). Growing demand for high-definition/high-resolution capabilities and diversifying applications drove ~1.3x expansion. By region within the Surveillance & FA segment, Europe surged +51% and China +29%
- Automotive camera lenses: Revenue of JPY 3.0B (+15.4% YoY). Strong sensing demand driven by ADAS adoption; the Chinese market, which had stagnated in the prior period, also recovered
- Medical lenses: Revenue of JPY 300M (+62.0% YoY). The expansion of minimally invasive medical product lineups leveraging ultra-small-diameter and thin-film technologies proved effective
- FA/Machine vision lenses: Revenue of JPY 700M (+26.1% YoY). Demand recovered as camera makers completed inventory adjustments
- Proprietary-brand photography lenses (Europe): Revenue mix expanded from 13% to 17%, with JPY-denominated sales up +34% YoY. Reversed prior weakness and returned to positive growth
- Proprietary-brand photography lenses (Americas): JPY-denominated sales up +89% YoY
- OEM photography lenses: Revenue of JPY 3.8B (−38.7% YoY). Weak sales of certain order models persisted from H2 of the prior year, with volume also down −35.5%
- Proprietary-brand photography lenses (China): JPY-denominated sales plunged −57% YoY due to excess market inventory
Progress Versus Full-Year Guidance
Q1 revenue represents 20.3% progress against the full-year plan of JPY 91,000M. The company disclosed that Q1 came in above plan. The prior-year quarterly revenue split was Q1:Q2:Q3:Q4 = 22.9%:26.2%:25.1%:25.8%, so Q1 progress of 20.3% is slightly below the prior-year Q1 weighting of 22.9%. However, the company left full-year guidance unchanged, citing trade policy uncertainty from Q2 onward, making the achievability of its H2-weighted plan (H1 JPY 41,400M / H2 JPY 49,600M) the key focus.
| Item | Value (1Q Actual) | Full-Year Forecast | Progress Rate |
|---|---|---|---|
| Revenue | JPY 18,485M | JPY 91,000M | 20.3% |
| Operating Income | JPY 3,441M | JPY 18,500M | 18.6% |
| Recurring Profit | JPY 3,363M | JPY 18,500M | 18.2% |
| Net Income | JPY 2,712M | JPY 13,690M | 19.8% |
- H2-weighted plan structure (H1 JPY 41,400M / H2 JPY 49,600M). Revenue and profit are expected to be concentrated in H2 as new product launches are clustered from Q2 onward
- In the prior year, Photography-related segment revenue recovered to +7.0% YoY in Q4, demonstrating a pattern where new product effects materialize in the second half of the year
Changes To Guidance
No revisions to full-year or H1 cumulative guidance. Figures published on February 6, 2026 remain unchanged. While Q1 tracked ahead of plan, guidance was maintained in light of trade policy uncertainty, Middle Eastern geopolitical risks impacting commodity prices and logistics, and indirect effects of semiconductor shortages.
Commentary On Shareholder Returns
The full-year FY2026 dividend forecast remains unchanged at JPY 37.00 per share (JPY 10.50 at Q2-end, JPY 26.50 at FY-end). This represents a JPY 0.75 increase from the prior-year actual of JPY 36.25 (split-adjusted). The projected payout ratio is 43.6%. The shareholder return policy targets a payout ratio of approximately 40% (with a JPY 20 annual floor) and a total return ratio of approximately 60%, supplemented by opportunistic share buybacks.
Financial Position
The equity ratio remained elevated at 82.5%, with interest-bearing debt dependency at just 1.2%, maintaining a virtually debt-free balance sheet. The decline in cash and deposits was primarily driven by dividend payments (JPY 4.27B), with no concerns regarding overall financial health.
- Key Figures
- Leverage Metrics
| Item | Value | Additional Information |
|---|---|---|
| Total Assets | JPY 102,868M | −3.0% vs. prior FY-end |
| Cash and Deposits | JPY 30,819M | −12.9% vs. prior FY-end |
| Inventories | JPY 18,989M | +13.3% vs. prior FY-end; 3.1 months turnover |
| └ Finished Goods | JPY 10,253M | +9.5% vs. prior FY-end |
| └ Work in Progress | JPY 5,932M | +15.9% vs. prior FY-end |
| └ Raw Materials and Supplies | JPY 2,803M | +22.7% vs. prior FY-end |
| Interest-Bearing Debt | JPY 1,208M | Debt dependency ratio: 1.2% |
| └ Short-Term Borrowings | JPY 832M | - |
| └ Long-Term Borrowings | JPY 376M | +52.2% vs. prior FY-end |
| Net Assets | JPY 84,861M | −1.2% vs. prior FY-end |
| EBITDA | JPY 4,293M | Operating income JPY 3,441M + depreciation JPY 852M |
News Released Alongside The Earnings Announcement
None
Major Announcements During The Quarter
- 2026/02/02Strategic investment in Light Touch Technology, developer of the world's first non-invasive blood glucose sensor that eliminates the need for blood draws. Accelerating the deployment of optical technology into medical and healthcare applications Tamron invests in LTT, aiming to commercialize the world's first "needle-free" blood glucose sensor
- 2026/02/06Refreshed long-term vision targeting 2035, declaring the evolution toward a comprehensive optical and sensing solutions company Tamron refreshes long-term vision targeting 2035
- 2026/02/19Announced the full-frame mirrorless large-aperture standard zoom lens "35-100mm F/2.8 Di III VXD (Model A078)" for Sony E-mount and Nikon Z-mount, with launch on March 26 Casual portrait photography in pocket size: large-aperture standard zoom lens 35-100mm F2.8 (Model A078) launch
- 2026/02/19Announced the wireless control accessory "TAMRON-LINK" and iOS support for TAMRON Lens Utility. Enhancing software integration for lens products Announcement of "TAMRON-LINK™" wireless accessory for TAMRON Lens Utility™ and iOS support
- 2026/03/25Announced price revisions effective April 1, 2026 for certain mirrorless camera lenses, reflecting rising raw material and manufacturing/logistics costs Notice regarding price revisions for select products
Large-Shareholding Filings / Material Proposals Over The Past Year
- Effissimo Capital Management: 16.34% → 17.38% (filed 2026/04/07, trigger date 2026/03/31) — pure investment
- Effissimo Capital Management: 15.30% → 16.34% (filed 2026/03/11, trigger date 2026/03/04) — pure investment
- Effissimo Capital Management: 14.12% → 15.30% (filed 2026/02/17, trigger date 2026/02/09) — pure investment
- Effissimo Capital Management: 13.06% → 14.12% (filed 2025/12/10, trigger date 2025/12/03) — pure investment
- Effissimo Capital Management: 12.04% → 13.06% (filed 2025/10/23, trigger date 2025/10/16) — pure investment
- Effissimo Capital Management: 10.87% → 12.04% (filed 2025/08/06, trigger date 2025/07/30) — pure investment
- Resona Asset Management (joint holding): 5.01% → 6.15% (filed 2025/06/20, trigger date 2025/06/13)
Effissimo's sustained accumulation is notable, with its stake rising +6.51pt from 10.87% to 17.38% over the past year. While the stated purpose is pure investment, the holding has reached a level comparable to a top shareholder, warranting close attention to future developments.
Envalith, Inc. ("Envalith") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and Envalith and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. Envalith has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by Envalith using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, Envalith and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. Envalith and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
Envalith and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
Envalith may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that Envalith is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to Envalith. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of Envalith is strictly prohibited.
- Use for Other Investment Products
Except where Envalith has provided prior written approval, the use of this report and the trademarks or trade names of Envalith or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.